PPT-Relapsed and Refractory Myeloma

Ruben Niesvizky Myeloma Center Myelomacenterorg run9001medcornelledu Multiple Myeloma Natural History of Disease Durie B International Myeloma Foundation Concise review of the disease and treatment options multiple myeloma 20112012 edition. Topics. Current Treatment Options for Relapsed/Refractory Multiple Myeloma. Topics. Relapsed/Refractory MM. Treatment Goals and Strategies. Relapsed/Refractory MM. Exposure to Stem Cell Toxic Agents Not An Issue for Most Patients . 5 Multiple Myeloma SANDRA E. KURTIN, RN, MS, AOCN Hodgkin Lymphoma. Program Objectives. Brentuximab Vedotin in Hodgkin Lymphoma. Brentuximab Vedotin in Patients With R/R HL. Brentuximab Vedotin: Adverse Events . Nivolumab in Relapsed/Refractory HL. Pembrolizumab in Relapsed/Refractory HL. therapy in relapsed/refractory myeloma: . A UK multi-centre experience. Neil Rabin. Consultant Haematologist. o. n behalf of Dr Nicola . Maciocia. University College London Hospitals, UK. 4. th. November 2015. IWCLL Criteria for Treating CLL. Other Considerations at Relapse. Risk Factors at Relapse. IGHV . Status Affects Clinical Course. Case 1: 65-Year-Old Man. Assessing This Patient's Options. TP53 . Mutation/del(17p) and CIT. ASH Review 2012. Stephen Spurgeon (spurgeos@ohsu.edu). Disclosures. Speakers Bureau: GSK, . Millenium. , . Cephalon. CLL: Pertinent Topics. ASH treatment updates. James DF, et al. ASH 2011. Abstract 291.. Case Discussion A 64-year old woman diagnosed with monoclonal gammopathy of undetermined significance (MGUS ) in September 2015 She has been monitored over time and has had a slight increase in her proteins. T. ransplant . in CR on . B. rentuximab. . V. edotin. : . Allo. . Transplant . or . Maintenance . T. herapy. ?. Anas Younes, M.D.. Memorial Sloan Kettering Cancer Center. Overall Survival. <1990 median 1.9 yrs. Bertrand Coiffier. Service d. ’. Hématologie. Hospices Civils de Lyon. Equipe . « Pathologie des Cellules Lymphoïdes ». UMR 5239 CNRS – UCB – ENS - HCL. The Lymphoma. Study Association. One question, lot of possibilities. actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Moderator. Neil Love, MD. Faculty . Dissecting the Decision: . Jonathon B. Cohen, MD. Dept of . Hematology. /Medical Oncology. Co-Director . Lymphoma Program. Relapsed aggressive . nhl. associated with shortened survival. Scholar-1 (Crump et al, Blood 2017). Martin et al, Blood 2016. Chimeric Antigen Receptor Tcell TherapyClinical Guideline Effective August 4, 2022 ��Table of Contents��THIS DOCUMENT IS PROPRIETARY AND CONFIDENTIAL TO OPTUMUnauthorized u Myelom. Heinz . Gisslinger. Medizinische Universität Wien. . Medizinische . Universität Wien. Die häufigsten Tumorlokalisationen nach Geschlecht (2014). . 20.361 Männer = 100% 18.547 Frauen = 100%. How to treat. triple- or penta-refractory . Multiple Myeloma?. María-Victoria . Mateos. , MD, PhD. University Hospital of Salamanca-. Ibsal. . Salamanca, Spain. 2. This . LYMPHOMA & MYELOMA CONNECT .